Alterations of T Cell Subpopulation in Glioma Patients Received Autologous Immunotherapy

Objective To evaluate the clinical application of autologous dendritic tumor vaccination on brain glioma, and to access the alterations of T cell subpopulation in patients with brain glioma before and after autologous immunotherapy. Methods The experimental group (21 Glioma patients) received vaccinations of autologous dendritic cell pulsed with autologous tumor peptides, while the control group (19 glioma patients) only received the regular treatments. Following-ups were carried out and the T cell subpopulations were measured. Results The median survival time of the experimental group (29 months) was significantly longer than that of control group (10 month) (P 0.05). The levels of CD3 + and CD4 + and the ratio of CD4 +/CD8 + ratio in peripheral blood in glioma patients were significantly lower compared with the healthy control, the levels of CD3 +, CD4 +, CD8 +and the CD4 +/CD8 + ratio were significantly increased after immunotherapy than before, but the CD4 +/CD8 + ratio remained lower compared with the healthy control. Conclusion The immune functions of glioma patients were suppressed. Immunotherapy could prolong the survival time of the glioma patient by reconstructing and enhancing some parts of the tumor immunity.